U.S. markets open in 2 hours 5 minutes
  • S&P Futures

    3,770.50
    -50.75 (-1.33%)
     
  • Dow Futures

    30,652.00
    -347.00 (-1.12%)
     
  • Nasdaq Futures

    11,510.25
    -180.75 (-1.55%)
     
  • Russell 2000 Futures

    1,694.50
    -26.90 (-1.56%)
     
  • Crude Oil

    109.23
    -0.55 (-0.50%)
     
  • Gold

    1,812.10
    -5.40 (-0.30%)
     
  • Silver

    20.45
    -0.29 (-1.39%)
     
  • EUR/USD

    1.0405
    -0.0039 (-0.37%)
     
  • 10-Yr Bond

    3.0930
    0.0000 (0.00%)
     
  • Vix

    29.84
    +1.48 (+5.22%)
     
  • GBP/USD

    1.2114
    -0.0008 (-0.07%)
     
  • USD/JPY

    136.3560
    -0.1890 (-0.14%)
     
  • BTC-USD

    19,051.28
    -887.78 (-4.45%)
     
  • CMC Crypto 200

    407.46
    -32.20 (-7.32%)
     
  • FTSE 100

    7,175.72
    -136.60 (-1.87%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Annexon Biosciences
Annexon Biosciences

BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will participate in a virtual panel titled, “Orphan CNS Panel,” during the Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022, at 2:10 p.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines designed to stop the classical complement pathway at its start, C1q, to bring therapies to patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company’s proprietary complement-targeting platform utilizes well-researched classical complement-mediated autoimmune and neurodegenerative processes triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a broad portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway, which may provide more complete protection against complement-mediated disorders of the body, brain and eye. The company’s pipeline includes three clinical-stage drug candidates, ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration), as well as a robust early-stage pipeline of preclinical and discovery stage programs. Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

Investor Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media Contact:

Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com